Efficacy of Myo-inositol versus Metformin in patients with polycystic ovary syndrome (PCOS) who undergo FIV-ICSI cycles
Irene López Carrasco (ES), Isidoro Bruna Catalan (ES), Maria Sanchez De Rivera Colino (ES), Oscar Collado Ramos (ES), Ana Vegas Carrillo De Albornoz (ES), Enrique Moratalla Bartolomé (ES), Maria Cano Vieco (ES)
[López Carrasco] Hospital Montepríncipe, [Bruna Catalan] Hospital Montepríncipe, [Sanchez de Rivera Colino] Hospital Montepríncipe, [Collado Ramos] Hospital Montepríncipe, [Vegas Carrillo de Albornoz] Hospital Montepríncipe, [Moratalla Bartolomé] Hospital Montepríncipe, [Cano Vieco] Hospital Montepríncipe
Context: polycystic ovary syndrome (PCOS) is the most frequent cause of infertility associated to anovulation. Within the insulin resistance therapy group, since a few years back we have inositol and its variations as a treatment strategy. Objective: Taking into consideration the innocuity and good tolerance of this vitamin reported in literature, we have investigated de efficacy of Myo-Inositol compared to that of Metformin in patients with PCOS that are undergoing treatment of assisted reproduction in terms of quality of retrieved oocytes (immature oocytes and oocytes y II stage metaphase) Methods: We conducted a retrospective observational study, with cases and controls in patients with PCOS that underwent fertility treatment (IVF -ICSI) in the fertility department of University Hospital Montepríncipe from January 2008 until July 2015. A total of 389 patients were recruited, 185 in the group that received Myo-Inositol 2gr/24h orally and 189 in the group that received Metformin 850 mg/24h orally. Results: Both groups were similar in clinical characteristics as well as comorbidities. There were no statistically relevant differences within the number of oocytes in metaphase II retrieved (10,11±5,27 in the Myo-inositol group and 9,84±5,41 in the Metformin group). In the group that received treatment with Myo-Inositol there were less immature oocytes (6,35±5,07 case group vs 8,02±6,82 control group, p=0,022). The number of class B embryos retrieved on the Myo-Inositol group was higher than in the metformin group (0,58 Vs. 0,50, p= 0,043); and a higher rate of clinical pregnancy (64,37% vs 39,90%, p<0,001). For the secondary variables studied, there were no statistically relevant differences. Conclusion: There seems to be better results in patients treated with Myo-Inositol in relation with a fewer oocytes in metaphase II and a higher rate of clinical pregnancy.